Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S; I-SPY 2 Trial Consortium; Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. Yau C, et al. Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11. Lancet Oncol. 2022. PMID: 34902335 Free PMC article.
Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
García-Sáenz JA, Custodio A, Casado A, Vidart JA, Coronado PJ, Martín M, López-Tarruella S, Puente J, Fernández C, Díaz-Rubio E. García-Sáenz JA, et al. Clin Transl Oncol. 2011 Feb;13(2):121-32. doi: 10.1007/s12094-011-0629-6. Clin Transl Oncol. 2011. PMID: 21324801 Review.
Neratinib (HKI-272) in the treatment of breast cancer.
López-Tarruella S, Jerez Y, Márquez-Rodas I, Martín M. López-Tarruella S, et al. Future Oncol. 2012 Jun;8(6):671-81. doi: 10.2217/fon.12.66. Future Oncol. 2012. PMID: 22764764 Review.
Zooming in on the schedule of bone-modifying drugs.
Martin M, López-Tarruella S. Martin M, et al. Lancet Oncol. 2013 Jun;14(7):575-6. doi: 10.1016/S1470-2045(13)70209-2. Epub 2013 May 16. Lancet Oncol. 2013. PMID: 23684410 No abstract available.
Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer.
Martín M, Custodio S, de Las Casas ML, García-Sáenz JÁ, de la Torre JC, Bellón-Cano JM, López-Tarruella S, Vidaurreta-Lazaro M, de la Orden V, Jerez Y, Márquez-Rodas I, Casado A, Sastre J, Díaz-Rubio E. Martín M, et al. Oncologist. 2013;18(8):917-23. doi: 10.1634/theoncologist.2012-0479. Epub 2013 Jul 19. Oncologist. 2013. PMID: 23873719 Free PMC article.
Optimizing Adjuvant Taxanes in Early Breast Cancer.
Martin M, López-Tarruella S. Martin M, et al. J Clin Oncol. 2015 Jul 20;33(21):2334-6. doi: 10.1200/JCO.2015.61.9312. Epub 2015 Jun 22. J Clin Oncol. 2015. PMID: 26101243 No abstract available.
74 results